SEHK:9995Biotechs
Why RemeGen (SEHK:9995) Is Up 13.1% After First HER2 ADC–Immunotherapy Approval in China
RemeGen announced that China’s NMPA has approved a new indication for its antibody-drug conjugate Disitamab Vedotin, in combination with Toripalimab, to treat HER2-expressing locally advanced or metastatic urothelial carcinoma, marking the drug’s fifth approved use in China.
This approval is underpinned by a large Phase III trial showing the combo outperformed standard platinum-based chemotherapy across the full spectrum of HER2 expression, reinforcing the clinical relevance of pairing...